LUCERO ALVAREZ, YALDA CECILIA
Thumbnail Image
Preferred name
LUCERO ALVAREZ, YALDA CECILIA
Main Affiliation
Email
y.lucero@udd.cl
ORCID
Scopus Author ID
6507615689

Research Output

2024 2024 2023 2023 2022 2022 2021 2021 2020 2020 0.0 0.0 0.2 0.2 0.4 0.4 0.6 0.6 0.8 0.8 1.0 1.0 1.2 1.2 1.4 1.4 1.6 1.6 1.8 1.8 2.0 2.0

Filters

5
Reset filters

Settings
Now showing 1 - 5 of 5
No Thumbnail Available
Publication

Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008–2023): A Systematic Review

2024 , Camila Cabrera , Joaquín Torres , Carolina A. Serrano , Paulina Gallardo , Vicente Orellana , Sergio George , Miguel O'Ryan , LUCERO ALVAREZ, YALDA CECILIA

ABSTRACTBackgroundLatin America has a high prevalence of Helicobacter pylori in children that may lead to peptic ulcer disease and eventually gastric cancer in adulthood. Successful eradication is hindered by rising antimicrobial resistance. We summarize H. pylori resistance rates in Latin American children from 2008 to 2023.Material and MethodsSystematic review following PRISMA guidelines and National Heart, Lung, and Blood Institute checklist to assess risk of bias (PROSPERO CRD42024517108) that included original cross‐sectional observational studies reporting resistance to commonly used antibiotics in Latin American children and adolescents. We searched in PubMed, LILACS, and SciELO databases.ResultsOf 51 studies, 45 were excluded. The quality of the six analyzed studies (297 H. pylori‐positive samples) was satisfactory. Phenotypic methods (N = 3) reported higher resistance rates than genotypic studies (N = 3). Clarithromycin resistance ranged from 8.0% to 26.7% (6 studies; 297 samples), metronidazole from 1.9% to 40.2% (4 studies; 211 samples), amoxicillin from 0% to 10.4% (3 studies; 158 samples), tetracycline resistance was not detected (3 studies; 158 samples), and levofloxacin resistance was 2.8% (1 study; 36 samples).ConclusionScarce Latin American studies on H. pylori resistance, along with methodological heterogeneity, hinder conclusive findings. Clarithromycin and metronidazole (first‐line drugs) resistance is worrisome, likely impacting lower eradication rates. Urgent systematic surveillance or individual testing before treatment is necessary to enhance eradication.

View
No Thumbnail Available
Publication

Corrigendum to ‘Corrigendum Helicobacter pylori, clinical, laboratory and noninvasive biomarkers suggestive of gastric damage in healthy school-aged children: a case-control study’

2022 , LUCERO, YALDA , Anne J. Lagomarcino , Juan P. Torres , ROESSLER VERGARA, PATRICIA ANDREA , Nora Mamani , Sergio George , Nicole Huerta , Monica Gonzalez , Miguel O'Ryan G

View
No Thumbnail Available
Publication

Helicobacter pylori, clinical, laboratory, and noninvasive biomarkers suggestive of gastric damage in healthy school-aged children: A case-control study

2021 , Yalda Lucero , Anne J. Lagomarcino , Juan P. Torres , ROESSLER VERGARA, PATRICIA ANDREA , Nora Mamani , Sergio George , Nicole Huerta , Monica Gonzalez , Miguel O’Ryan

View
No Thumbnail Available
Publication

Norovirus compared to other relevant etiologies of acute gastroenteritis among families from a semirural county in Chile

2020 , LUCERO, YALDA , Anne J. Lagomarcino , Mónica Espinoza , Nanami Kawakami , Nora Mamani , Nicole Huerta , Felipe Del Canto , Mauricio Farfán , Yoshihiro Sawaguchi , Sergio George , Miguel O’Ryan

View
No Thumbnail Available
Publication

Norovirus: Facts and Reflections from Past, Present, and Future

2021 , LUCERO, YALDA , David O. Matson , Shai Ashkenazi , Sergio George , Miguel O’Ryan

Human Norovirus is currently the main viral cause of acute gastroenteritis (AGEs) in most countries worldwide. Nearly 50 years after the discovery of the “Norwalk virus” by Kapikian and colleagues, the scientific and medical community continue to generate new knowledge on the full biological and disease spectrum of Norovirus infection. Nevertheless, several areas remain incompletely understood due to the serious constraints to effectively replicate and propagate the virus. Here, we present a narrated historic perspective and summarize our current knowledge, including insights and reflections on current points of interest for a broad medical community, including clinical and molecular epidemiology, viral–host–microbiota interactions, antivirals, and vaccine prototypes. We also include a reflection on the present and future impacts of the COVID-19 pandemic on Norovirus infection and disease.

View